Table 4

Knowledge and attitudes

Which ophthalmological side effects are associated with HCQ use? Mark all that apply, n (%)
Periorbital oedema	0 (0)
Keratopathy	21 (32.8)
Cataract formation	2 (3.1)
Retinopathy	64 (100)*
None of the above	0 (0)
What are the common symptoms of progressive retinal toxicity associated with CQ/HCQ use? Mark all that apply, n (%)
Visual colour deficits	49 (76.6)*
Paracentral scotoma	54 (84.4)*
Glare	14 (21.9)
Flashing lights	18 (28.1)
Metamorphopsia (visual distortion)	26 (40.6)
A 37-year-old woman with no significant past medical history (PMH) is newly diagnosed with SLE and started on HCQ. What is her approximate risk of retinal toxicity after 5 years of treatment at recommended dosages? n (%)
<1%	46 (71.9)*
3%–5%	15 (23.4)
5%–10%	3 (4.7)
10%–20%	0 (0)
>20%	0 (0)
A 37-year-old woman with no significant PMH is newly diagnosed with SLE and started on HCQ. At what point should she be considered at high risk for developing retinal toxicity? n (%)
1 month intro treatment	0 (0)
1 year into treatment	1 (1.6)
5 years into treatment	17 (26.5)
20 years into treatment	44 (68.8)*
No significant temporal relationship	2 (3.1)
When might you refer your patient prescribed HCQ to an ophthalmologist? n (%)
Prior to initiating therapy	17 (26.6)
Non-urgent within first year of treatment	40 (62.5)*
Non-urgent within first 5 years of treatment	6 (9.4)
Only after complaint of reduced visual acuity	1 (1.5)